drug
mepolizumab
Marketedupdated 5mo agoby GlaxoSmithKline LLC
Approvedcommunity read0 votes
indications
investigational
Asthma
all catalysts(0)
nothing on the calendar yet
Trials studying mepolizumab
- —Long-Term Safety and Effectiveness of Mepolizumab 300 mg in Europe (Mepo LTF Study)
- phase3Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level
- phase3Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
- phase3Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial
- —NUCALA® Special Drug Use Investigation (EGPA, Long-term)
- phase3Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.
- —Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma
- EP1The Role of IL5 in Epithelial Cell Integrity
News(1)
- A COPD drug from China draws $115M in venture fundingExpedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.biopharma_dive · 1mo ago
Data sources
last refreshed 45m ago
Found something off?
comments(0)
5-min edit window · permanent after that